Connect with us

News

Canada to Send Asylum Seekers Back to United States

Published

on

United States and Canada

The Supreme Court of Canada upheld an immigration agreement between the United States and Canada on Friday, stating that asylum applicants must apply in the nation where they first enter.

In an effort to stem the flow of asylum seekers across the common border, the United States and Canada agreed in 2002 to return migrants who go to an official Canadian crossing to the United States and tell them to apply there. The agreement was found valid by the Supreme Court.

“In my view, the record does not support the conclusion that the American detention regime is fundamentally unfair,” wrote Justice Nicholas Kasirer in his ruling.

On behalf of a number of applicants, including an Ethiopian Muslim woman imprisoned after attempting to enter Canada from the United States, the Canadian Council for Refugees challenged the legitimacy of the 2002 agreement.

Lawyers had petitioned the Supreme Court to rule that the statute underlying the treaty violates the right to life, liberty, and security of person, claiming that the United States is not secure for many asylum seekers.

Those who arrive in Canada anywhere other than a port of entry, such as the centre at Roxham Road, were allowed to stay and seek shelter until a new arrangement was announced in March. This accord plugged a gap that had allowed thousands of asylum seekers to travel between the two nations via a back road connecting New York state and the Canadian province of Quebec. The decision also keeps that loophole closed.

canada

Canada’s Roxham Road

Since early 2017, so many migrants have strolled into Canada via Roxham Road near Champlain, New York, that the Royal Canadian Mounted Police have set up a welcome centre fewer than five miles (8 kilometres) from the official border crossing.

However, under a recently passed regulation, asylum seekers without US or Canadian citizenship who are apprehended within 14 days of crossing anywhere along the 3,145-mile (5,061-kilometer) border will be deported. This includes pedestrians on Roxham Road.

The deal signed in March by US President Joe Biden and Canadian Prime Minister Justin Trudeau occurred as the US Border Patrol responded to a sharp spike in unlawful southbound crossings along the wide-open Canadian border.

The number of illegal border crossers into the United States from Canada is small in comparison to those entering the country illegally from Mexico, but there have been fatalities on the Canadian side of the border.

In a statement, Karen Musalo, director of the San Francisco-based Centre for Gender & Refugee Studies, said it was difficult to comprehend how the Canadian high court made its ruling because “by no objective assessment” is the United States safe for asylum seekers.

“The Biden administration has embraced policies that deprive refugees of their right to seek protection, resulting in their unlawful return to countries where they face persecution and torture,” according to the statement.

canada

Seeking Refuge in Canada

According to Amnesty International, the revised agreement makes it even more hazardous and unfair for people seeking refuge in Canada.

People seeking refuge in Canada come from various countries around the world and may be fleeing persecution, violence, war, or other forms of human rights abuses. Canada has a well-established refugee resettlement program and a legal framework to assess and process refugee claims.

The process for seeking refuge in Canada involves several steps:

1. Claiming asylum: Individuals who arrive in Canada and believe they are in need of protection can make a claim for refugee status. They must prove that they have a well-founded fear of persecution based on their race, religion, nationality, political opinion, or membership in a particular social group.

2. Initial assessment: The claimant’s case is reviewed by the Immigration and Refugee Board of Canada (IRB), an independent administrative tribunal. The claimant attends an interview to provide detailed information about their situation, and the IRB determines if there are reasonable grounds for the claim.

3. Refugee hearing: If the claimant’s case passes the initial assessment, a refugee hearing is scheduled. The claimant presents their case and provides evidence supporting their claim for refugee status. The IRB considers all the evidence and makes a decision.

4. Appeals process: If the claim is rejected, the claimant may have the option to appeal the decision to the Refugee Appeal Division (RAD) within the IRB. The RAD reviews the decision based on errors in law, fact, or mixed law and fact. Further appeals can be made to the Federal Court.

5. Resettlement and integration: If a claim for refugee status is approved, the person is granted refugee protection and is eligible to stay in Canada. They may receive resettlement assistance, including temporary housing, financial support, and access to essential services. The government and various organizations help refugees integrate into Canadian society by providing language training, employment support, and other settlement services.

Canada has a long history of accepting refugees and has been recognized as one of the leading countries in refugee resettlement. The government works closely with international organizations, such as the United Nations High Commissioner for Refugees (UNHCR), to identify and prioritize vulnerable individuals for resettlement.

It’s important to note that the specific policies and procedures related to refugee resettlement can evolve over time. For the most up-to-date and detailed information, it is recommended to consult the official website of Immigration, Refugees and Citizenship Canada (IRCC).

Geoff Thomas is a seasoned staff writer at VORNews, a reputable online publication. With his sharp writing skills and deep understanding of SEO, he consistently delivers high-quality, engaging content that resonates with readers. Thomas' articles are well-researched, informative, and written in a clear, concise style that keeps audiences hooked. His ability to craft compelling narratives while seamlessly incorporating relevant keywords has made him a valuable asset to the VORNews team.

Continue Reading

News

Katie Ledecky Hopes For Clean Races At Paris Olympics In The Aftermath Of The Chinese Doping Scandal

Published

on

ledecky

PARIS — Katie Ledecky is looking for clean Olympic races. On Wednesday, Hope had pretty much reached her limit.

The American swimmer hopes to add to her six gold medals as she competes in the 400, 800, and 1,500 meters at the Paris Games. Her program starts with the heavy 400 on Saturday, featuring Ariarne Titmus and Summer McIntosh.

ledecky

Katie Ledecky | ESPN Image

Katie Ledecky Hopes For Clean Races At Paris Olympics In The Aftermath Of The Chinese Doping Scandal

The 27-year-old Katie is competing in her fourth Summer Olympics, but the first since a doping scandal involving almost two dozen Chinese swimmers who tested positive for a banned chemical before the Tokyo Games — yet were permitted to compete with no consequences. The controversy has raised serious worries regarding the effectiveness of anti-doping initiatives.

ledecky

Katie Ledecky | Vogue Image

“I hope everyone here is going to be competing clean this week,” Ledecky claimed. “But what truly counts is, were they training cleanly? Hopefully this has been the case. Hopefully, there has been worldwide testing.”

The International Olympic Committee has expressed concern over the ongoing US investigation into possible doping by Chinese swimmers. While awarding the 2034 Winter Olympics to Salt Lake City on Wednesday, the IOC urged Utah officials to do whatever they could to stop the FBI investigation.

“I think everyone’s heard what the athletes think,” Katie added. “They seek transparency. They want more answers to the remaining questions. At this point, we are here to race. We are going to race whoever is in the lane next to us.

“We are not paid to conduct the tests, so we trust those who follow their regulations. That applies both today and in the future.

 

ledecky

Katie Ledecky | ESPN Image

Katie Ledecky Hopes For Clean Races At Paris Olympics In The Aftermath Of The Chinese Doping Scandal

SOURCE | AP

Continue Reading

News

London Heatwave Alert: High Temperatures Set to Soar to 29C Next Week

Published

on

London Heatwave Alert High Temperatures Set to Soar to 29C Next Week

As the summer holidays begin, London may experience an official heatwave with temperatures reaching up to 29 degrees Celsius.

The Met Office predicts a long period of sunny and dry weather for London after a soggy spring and summer.

After a cloudy day on Saturday, temperatures are expected to reach 27C on Sunday, with lots of sunlight.

On Monday and Tuesday, temperatures are forecast to peak at 29 degrees Celsius. Monday is forecast to offer more sunlight, while Tuesday may see some gloomy weather.

VOR News

Temperatures are expected to remain in the high 20s next week, with lows of approximately 18C.

According to the Met Office, a heatwave is “an extended period of hot weather relative to the expected conditions of the area at that time of year, which may be accompanied by high humidity.”

In the United Kingdom, a heatwave is proclaimed when daily temperatures meet or surpass a certain level for at least three consecutive days.

In London, the heatwave threshold is 28 degrees Celsius.

The Met Office reported that the UK is experiencing hotter and wetter weather on average due to climate change.

The UK experienced its warmest May and April on record this year, despite damp and dismal conditions in many areas.

According to the Met Office’s State Of The UK Climate 2023 report published on Thursday, the UK experienced historic levels of extreme weather last year.

In the United Kingdom, 2023 was the second warmest year on record, bringing storms, flooding, strong heatwaves, and rising sea levels; only 2022 was warmer.

It was 0.8°C higher than the average from 1991 to 2020, and 1.66°C higher than the 1961 to 1990 average.

However, 2023 will be a “cool year” in comparison to 2100, based on the planet’s warming trajectory.

The government’s plan to adapt to the hazards presented by climate change is currently being challenged in the High Court by campaigners who allege the Tory administration’s July 2023 National Adaptation Programme (NAP) fails to adequately address 61 concerns.

Source: The Standard

Continue Reading

News

Novo Nordisk’s Wegovy is a Heart-Risk-Reducing Product.

Published

on

Wegovy
Hollie Adams | Reuters

(VOR News) – The European Union’s medical regulator has granted approval to Wegovy, a blockbuster weight loss treatment manufactured by Novo Nordisk, in order to expand its application to include the reduction of major heart events in overweight or obese adults.

In order to expand the scope of the medication’s applicability, this authorisation was granted. The purpose of obtaining this approval was to broaden the medicine’s application.

The Danish pharmaceutical company announced on Thursday that the European Medical Agency has formulated a “positive opinion” regarding the label’s expansion.

The agency made this determination after conducting a comprehensive examination of the results of a SELECT study that was subjected to rigorous monitoring. Other applications of the substance are facilitated by this conclusion.

The SELECT experiment, which was financed by Novo Nordisk and published in August 2023.

Wegovy and Ozempic contain semaglutide as the active ingredient.

Reduced the risk of major cardiovascular events by twenty percent when compared to a placebo. The researchers arrived at this conclusion. This realisation was the outcome of the researchers’ investigation.

The notion that the European Medicines Agency label for Wegovy should be amended is a significant step forward for patients who are coping with cardiovascular disease and obesity, according to Martin Holst Lange, executive vice president and director of development at Novo Nordisk.

The company’s statement, which was disclosed, indicated that the recommendation to update the label is a substantial advancement.

It is evident that Wegovy has the potential to save lives by reducing the likelihood of significant adverse cardiovascular events, as evidenced by the findings of the SELECT research. An additional benefit of participating in this exercise is that it helps individuals effectively manage their weight, which is a benefit in and of itself.

The company also stated that the label update incorporates data from the SELECT trial, which showed a 15% reduction in the risk of death from cardiovascular causes and a 19% reduction in the risk of death from any cause when compared to situations in which a placebo was used in conjunction with the product.

The SELECT trial was conducted in the United States, according to the company. Furthermore, the organisation disclosed that the SELECT investigation was conducted in the United States of America.

It is anticipated that the label amendment will be implemented within the next month, as per the statement issued by Novo Nordisk.

Wegovy has also been approved for use in the United States.

Similarly, the UK medical regulator has taken similar actions. The United Kingdom on Tuesday granted its clearance for the use of Wegovy to reduce the risk of significant cardiac difficulties or strokes in adults who are overweight or obese, such as heart attacks or strokes.

The Food and Drug Administration of the United States of America granted sanction for the medicine to be used in specific applications during the month of March.

This resulted in a rise in the number of distinct applications for the highly popular treatment, which coincides with the sector’s increasing level of competition.

On Thursday, Roche, a global pharmaceutical company with its headquarters in Switzerland, announced that its Wegovy competitor weight reduction tablets will be incorporated into a collection of pharmaceuticals designed to mitigate the adverse effects of obesity.

The pharmaceutical collection will encompass a diverse selection of weight loss medications.

The company’s Chief Executive Officer, Thomas Schinecker, conveyed his satisfaction with the exceptional early-stage trial results of the two potential weight-reduction pharmaceuticals that the company is currently developing. In addition, he asserted that these medications demonstrated the “best in disease potential.”

In making this assertion, Schinecker was alluding to the fact that the medications exhibited the “best in disease potential.” He also stated that they will be a part of a more comprehensive portfolio that is intended to set the Swiss company apart from its competitors in the growing obesity therapy market.

This adds insult to injury. This strategy will be implemented in order to distinguish the Swiss company from other businesses in the market.

SOURCE: CNBC

SEE ALSO:

A Strong U.S. GDP Report Boosts Oil, but Asia’s Economic Woes Limit Gains.

Surge in Covid Cases in Greece: Tourists Issued FLiRT Variant Warning

Business Owners Blame the Government’s Economic Incompetence for Rising Inflation.

 

Continue Reading

Trending